← Browse by Condition
Medical Condition

castration sensitive prostate carcinoma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2

ClinicalMetric aggregates all active clinical trials for castration sensitive prostate carcinoma from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries. Trials are updated daily as new studies open, status changes, and enrollment targets are updated.

  • Recruiting trials — currently enrolling participants, with eligibility criteria
  • Phase 1–4 studies — from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary for every trial listing
NCT06244004 Phase 2
Recruiting

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

Enrollment
125 pts
Location
United States
Sponsor
Northwestern University
View Trial →